New hope for Hard-to-Treat myeloma: experimental drug enters human trials
Disease control
Recruiting now
This early-stage trial tests a new drug called OPN-6602, alone or with a steroid, in 130 people whose multiple myeloma has returned or stopped responding to at least three prior treatments. The main goal is to check safety and find the right dose. It's too early to know if it wil…
Phase: PHASE1 • Sponsor: Opna Bio LLC • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC